Increased MYD88 blood transcript in a mouse model of Alzheimer's disease.
Background: Neuroinflammation plays a prominent role in Alzheimer's disease (AD), both in pathogenesis and disease progression. It has been shown that TLR/MYD88 signaling is involved in the chronic low-grade sterile inflammation associated with AD. Several studies have evidenced high levels of MYD88...
| Published in: | BMC Neuroscience Vol. 23; no. 1; pp. 1 - 7 |
|---|---|
| Main Authors: | , , , , |
| Format: | research Journal Article |
| Published: |
BioMed Central
3/11/2022
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155719562&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 155719562 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14712202 1CI8 jtl: BMC Neuroscience issn: 14712202 maglogo: N pubinfo: dt: 3/11/2022 vid: 23 iid: 1 pid: 24147 pub: BioMed Central artinfo: ui: 155719562 155719562 NLM35277123 155719562 10.1186/s12868-022-00699-8 NLM35277123 155719562 ppf: 1 ppct: 6 formats: tig: atl: Increased MYD88 blood transcript in a mouse model of Alzheimer's disease. aug: au: Cucos, Catalina Anca Dobre, Maria Dragnea, Elena Mihaela Manda, Gina Milanesi, Elena affil: Laboratory of Radiobiology, "Victor Babes" National Institute of Pathology, Bucharest, Romania sug: subj: Alzheimer's Disease Metabolism Alzheimer's Disease Drug Therapy Alzheimer's Disease Animal Studies Human Carrier Proteins Models, Biological Disease Progression Mice Protein Precursors Metabolism Inflammation Metabolism Carrier Proteins Metabolism Comparative Studies Multicenter Studies Evaluation Research Validation Studies ab: Background: Neuroinflammation plays a prominent role in Alzheimer's disease (AD), both in pathogenesis and disease progression. It has been shown that TLR/MYD88 signaling is involved in the chronic low-grade sterile inflammation associated with AD. Several studies have evidenced high levels of MYD88 in the brain of patients and animal models of AD, but no study has assessed so far its levels in blood.Methods: In this study we evaluated the blood mRNA levels of MYD88 in a mouse model of AD, and also the putative effect of Rivastigmine treatment on MYD88 expression. Twenty-eight transgenic APP/TAU mice (AT) and twenty-two control C57/BL6j mice (WT) were included in this study, out of which five transgenic AT and five WT mice were treated with Rivastigmine.Results: Increased MYD88 transcript in the whole blood from AT mice as compared to WT controls was found, which seems to increase in time due to disease progression and not to aging. This finding suggests that blood leukocytes are primed to develop TLR/MYD-mediated inflammatory processes. Moreover, results indicate that MYD88 blood levels were not modulated by the diseases-specific treatment with Rivastigmine.Conclusions: Our results suggest that MYD88 might be a promising blood biomarker to monitor AD progression. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|